Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein

Journal of Virology

Volumn 86, Issue 2, 2012, Pages 1145-1157

  Postler, Thomas S ^a,b   Martinez Navio, José M ^a   Yuste, Eloísa ^a,c,d   Desrosiers, Ronald C ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY OF BARCELONA   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HIR; OLIGOPEPTIDE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN LOCALIZATION; RHESUS MONKEY; RNA VIRUS INFECTION; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS CELL INTERACTION; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CELL MEMBRANE; DISEASE MODELS, ANIMAL; GENE PRODUCTS, ENV; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; RABBITS; RETROVIRIDAE PROTEINS, ONCOGENIC; SEQUENCE ALIGNMENT; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL FUSION PROTEINS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA MULATTA; ORYCTOLAGUS CUNICULUS; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84856873086     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06463-11     Document Type: Article

References (65)

1. Berlioz-Torrent C, et al. 1999. Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. J. Virol. 73:1350-1361.
2. Bhattacharya J, Peters PJ, Clapham PR. 2004. Human immunodeficiency virus type 1 envelope glycoproteins that lack cytoplasmic domain cysteines: impact on association with membrane lipid rafts and incorporation onto budding virus particles. J. Virol. 78:5500-5506.
3. Bjorling E, et al. 1991. Hyperimmune antisera against synthetic peptides representing the glycoprotein of human immunodeficiency virus type 2 can mediate neutralization and antibody-dependent cytotoxic activity. Proc. Natl. Acad. Sci. U. S. A. 88:6082-6086.
4. Boge M, Wyss S, Bonifacino JS, Thali M. 1998. A membrane-proximal tyrosine-based signal mediates internalization of the HIV-1 envelope glycoprotein via interaction with the AP-2 clathrin adaptor. J. Biol. Chem. 273:15773-15778.
5. Bowers K, et al. 2000. The simian immunodeficiency virus envelope glycoprotein contains multiple signals that regulate its cell surface expression and endocytosis. Traffic 1:661-674.
6. Broliden PA, et al. 1992. Identification of human neutralizationinducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc. Natl. Acad. Sci. U. S. A. 89:461-465.
7. Burton DR, Williamson RA, Parren PW. 2000. Antibody and virus: binding and neutralization. Virology 270:1-3.
8. Chamberlain AK, Lee Y, Kim S, Bowie JU. 2004. Snorkeling preferences foster an amino acid composition bias in transmembrane helices. J. Mol. Biol. 339:471-479.
9. Chanh TC, et al. 1986. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 5:3065-3071.
10. Cheingsong-Popov R, et al. 1992. Geographic diversity of human immunodeficiency virus type 1: serologic reactivity to env epitopes and relationship to neutralization. J. Infect. Dis. 165:256-261.
11. Cheung JC, Reithmeier RA. 2007. Scanning N-glycosylation mutagenesis of membrane proteins. Methods 41:451-459.
12. Cheung L, McLain L, Hollier MJ, Reading SA, Dimmock NJ. 2005. Part of the C-terminal tail of the envelope gp41 transmembrane glycoprotein of human immunodeficiency virus type 1 is exposed on the surface of infected cells and is involved in virus-mediated cell fusion. J. Gen. Virol. 86:131-138.
13. Cleveland SM, et al. 2000. Immunogenic and antigenic dominance of a nonneutralizing epitope over a highly conserved neutralizing epitope in the gp41 envelope glycoprotein of human immunodeficiency virus type 1: its deletion leads to a strong neutralizing response. Virology 266:66-78.
14. Cleveland SM, et al. 2003. A region of the C-terminal tail of the gp41 envelope glycoprotein of human immunodeficiency virus type 1 contains a neutralizing epitope: evidence for its exposure on the surface of the virion. J. Gen. Virol. 84:591-602.
15. Dalgleish AG, et al. 1988. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology 165:209-215.
16. Davis D, et al. 1990. The immunodominance of epitopes within the transmembrane protein (gp41) of human immunodeficiency virus type 1 may be determined by the host's previous exposure to similar epitopes on unrelated antigens. J. Gen. Virol. 71:1975-1983.
17. Dimmock NJ. 2005. The complex antigenicity of a small external region of the C-terminal tail of the HIV-1 gp41 envelope protein: a lesson in epitope analysis. Rev. Med. Virol. 15:365-381.
18. Eisenberg D, Wesson M. 1990. The most highly amphiphilic alphahelices include two amino acid segments in human immunodeficiency virus glycoprotein 41. Biopolymers 29:171-177.
19. Evans DJ, et al. 1989. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature 339:385-388, 340.
20. Gangupomu VK, Abrams CF. 2010. All-atom models of the membranespanning domain of HIV-1 gp41 from metadynamics. Biophys. J. 99: 3438-3444.
21. Gao SJ, et al. 1996. Seroconversion to antibodies against Kaposi's sarcoma-associated herpesvirus-related latent nuclear antigens before the development of Kaposi's sarcoma. N. Engl. J. Med. 335:233-241.
22. Gao SJ, et al. 1996. KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat. Med. 2:925-928.
23. Goudsmit J, Meloen RH, Brasseur R. 1990. Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe. Intervirology 31:327-338.
24. Groopman JE, et al. 1986. Serological characterization of HTLV-III infection in AIDS and related disorders. J. Infect. Dis. 153:736-742.
25. Ho DD, et al. 1987. Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J. Virol. 61:2024-2028.
26. Hollier MJ, Dimmock NJ. 2005. The C-terminal tail of the gp41 transmembrane envelope glycoprotein of HIV-1 clades A, B, C, andDmay exist in two conformations: an analysis of sequence, structure, and function. Virology 337:284-296.
27. Johnson WE, et al. 2003. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J. Virol. 77:9993-10003.
28. Jowett JB, Jones IM. 1993. Glycosylation of the external domain of SIV gp41 is influenced by the cytoplasmic tail. AIDS Res. Hum. Retroviruses 9:197-198.
29. Kenealy W, et al. 1987. Analysis of human serum antibodies to human immunodeficiency virus (HIV) using recombinant ENV and GAG antigens. AIDS Res. Hum. Retroviruses 3:95-105.
30. Kennedy RC, et al. 1986. Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein. Science 231:1556-1559.
31. Kent KA, et al. 1992. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Res. Hum. Retroviruses 8:1147-1151.
32. LaBranche CC, et al. 1995. A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells. J. Virol. 69: 5217-5227.
33. Laudon H, et al. 2005. A nine-transmembrane domain topology for presenilin 1. J. Biol. Chem. 280:35352-35360.
34. Liu S, et al. 2010. Membrane topology analysis of HIV-1 envelope glycoprotein gp41. Retrovirology 7:100.
35. Lu L, et al. 2008. Surface exposure of the HIV-1 env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion core. J. Biol. Chem. 283:16723-16731.
36. McLain L, Porta C, Lomonossoff GP, Durrani Z, Dimmock NJ. 1995. Human immunodeficiency virus type 1-neutralizing antibodies raised to a glycoprotein 41 peptide expressed on the surface of a plant virus. AIDS Res. Hum. Retroviruses 11:327-334.
37. Means RE, Greenough T, Desrosiers RC. 1997. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J. Virol. 71: 7895-7902.
38. Moise AR, Golczak M, Imanishi Y, Palczewski K. 2007. Topology and membrane association of lecithin: retinol acyltransferase. J. Biol. Chem. 282:2081-2090.
39. Moore PS, et al. 1996. Primary characterization of a herpesvirus agent associated with Kaposi's sarcoma. J. Virol. 70:549-558.
40. National Research Council. 1996. Guide for the care and use of laboratory animals, p 86-123. National Academy Press, Washington, DC.
41. Niedrig M, et al. 1992. Murine monoclonal antibodies directed against the transmembrane protein gp41 of human immunodeficiency virus type 1 enhance its infectivity. J. Gen. Virol. 73:951-954.
42. Nilsson IM, von Heijne G. 1993. Determination of the distance between the oligosaccharyltransferase active site and the endoplasmic reticulum membrane. J. Biol. Chem. 268:5798-5801.
43. Ohno H, et al. 1997. Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family. Virology 238:305-315.
44. Parren PW, Burton DR. 2001. The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 77:195-262.
45. Pincus SH, et al. 1993. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees. J. Clin. Invest. 91:1987-1996.
46. Popov M, Li J, Reithmeier RA. 1999. Transmembrane folding of the human erythrocyte anion exchanger (AE1, Band 3) determined by scanning and insertional N-glycosylation mutagenesis. Biochem. J. 339: 269-279.
47. Popov M, Tam LY, Li J, Reithmeier RA. 1997. Mapping the ends of transmembrane segments in a polytopic membrane protein. Scanning N-glycosylation mutagenesis of extracytosolic loops in the anion exchanger, band 3. J. Biol. Chem. 272:18325-18332.
48. Reading SA, Heap CJ, Dimmock NJ. 2003. A novel monoclonal antibody specific to the C-terminal tail of the gp41 envelope transmembrane protein of human immunodeficiency virus type 1 that preferentially neutralizes virus after it has attached to the target cell and inhibits the production of infectious progeny. Virology 315:362-372.
49. Rosati M, et al. 2005. DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J. Virol. 79:8480-8492.
50. Rowell JF, Stanhope PE, Siliciano RF. 1995. Endocytosis of endogenously synthesized HIV-1 envelope protein. J. Immunol. 155:473-488.
51. Sato S, et al. 2008. Potent antibody-mediated neutralization and evolution of antigenic escape variants of simian immunodeficiency virus strain SIVmac239 in vivo. J. Virol. 82:9739-9752.
52. Sattentau QJ, Zolla-Pazner S, Poignard P. 1995. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules. Virology 206:713-717.
53. Sauter MM, et al. 1996. An internalization signal in the simian immunodeficiency virus transmembrane protein cytoplasmic domain modulates expression of envelope glycoproteins on the cell surface. J. Cell Biol. 132: 795-811.
54. Schupbach J, et al. 1985. Antibodies to HTLV-III in Swiss patients with AIDS and pre-AIDS and in groups at risk for AIDS. N. Engl. J. Med. 312:265-270.
55. Schwalbe RA, Wang Z, Bianchi L, Brown AM. 1996. Novel sites of N-glycosylation in ROMK1 reveal the putative pore-forming segment H5 as extracellular. J. Biol. Chem. 271:24201-24206.
56. Schwalbe RA, Wang Z, Wible BA, Brown AM. 1995. Potassium channel structure and function as reported by a single glycosylation sequon. J. Biol. Chem. 270:15336-15340.
57. Srinivas SK, Srinivas RV, Anantharamaiah GM, Segrest JP, Compans RW. 1992. Membrane interactions of synthetic peptides corresponding to amphipathic helical segments of the human immunodeficiency virus type-1 envelope glycoprotein. J. Biol. Chem. 267:7121-7127.
58. Steckbeck JD, Sun C, Sturgeon TJ, Montelaro RC. 2010. Topology of the C-terminal tail of HIV-1 gp41: differential exposure of the Kennedy epitope on cell and viral membranes. PLoS One 5:e15261.
59. Vella C, et al. 1991. Recognition of poliovirus/HIV chimaeras by antisera from individuals with HIV infection. AIDS 5:425-430.
60. Venable RM, Pastor RW, Brooks BR, Carson FW. 1989. Theoretically determined three-dimensional structures for amphipathic segments of the HIV-1 gp41 envelope protein. AIDS Res. Hum. Retroviruses 5:7-22.
61. West JT, Johnston PB, Dubay SR, Hunter E. 2001. Mutations within the putative membrane-spanning domain of the simian immunodeficiency virus transmembrane glycoprotein define the minimal requirements for fusion, incorporation, and infectivity. J. Virol. 75:9601-9612.
62. Yang C, Spies CP, Compans RW. 1995. The human and simian immunodeficiency virus envelope glycoprotein transmembrane subunits are palmitoylated. Proc. Natl. Acad. Sci. U. S. A. 92:9871-9875.
63. Yue L, Shang L, Hunter E. 2009. Truncation of the membrane-spanning domain of human immunodeficiency virus type 1 envelope glycoprotein defines elements required for fusion, incorporation, and infectivity. J. Virol. 83:11588-11598.
64. Yuste E, et al. 2008. Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies. J. Virol. 82:12472-12486.
65. Yuste E, Reeves JD, Doms RW, Desrosiers RC. 2004. Modulation of Env content in virions of simian immunodeficiency virus: correlation with cell surface expression and virion infectivity. J. Virol. 78:6775-6785.